source
- GSK licenses Chimagen trispecific T-cell engager for up to $750 million, targeting phase-1 multiple myeloma studyGSK has entered a licensing agreement with China’s Chimagen Biosciences that could be worth as much as $750 million. The deal will allow GSK to begin phase‑1 testing of a trispecific T‑cell engager…
- GSK signs new agreement with China's Chimagen for trispecific T-cell engager targeting blood cancersGSK, the UK‑based pharmaceutical company, has entered into a fresh licensing agreement with Chinese biotech Chimagen Biosciences. The partnership focuses on a trispecific T‑cell engager designed fo…